# NF-κB activation in astrocytes impairs wound healing after traumatic brain injury in male mice

**Authors:** Tabea M. Hein, Ester Nespoli, Marsela Hakani, Heinrich Wendt, Stephanie Nadine May, Jasmin Jorzik, Duygu Yagdiran, Judith S. Schlett, Konstantinos Tsesmelis, Miltiadis Tsesmelis, Vivien Prex, Melanie Mettang, Alireza Abaei, Volker Rasche, Michael Lattke, Franz Oswald, Markus Huber-Lang, Leda Dimou, Thomas Wirth, Bernd Baumann

PMC · DOI: 10.1038/s41467-026-70304-7 · 2026-03-06

## TL;DR

NF-κB activation in astrocytes after brain injury in male mice worsens recovery by disrupting healing processes.

## Contribution

The study identifies NF-κB activation in astrocytes as a harmful mechanism impairing CNS wound healing after TBI.

## Key findings

- NF-κB activation in astrocytes disrupts their homeostatic functions after TBI.
- It amplifies neuroimmune responses and hinders CNS scar development.
- Paracrine signaling from NF-κB-activated astrocytes prevents CNS restoration.

## Abstract

Traumatic brain injury (TBI) is a complex condition in which multiple pathophysiological mechanisms influence the course of the disease. After the initial mechanical impact, neuroinflammatory reactions of glial cells along with infiltrating peripheral immune cells determine the overall clinical outcome. However, these secondary processes and their molecular determinants promoting either beneficial or detrimental consequences are not well-defined. Here, we show that TBI-mediated NF-κB activation in astrocytes impairs their homeostatic functions, amplifies the post-traumatic neuroimmune response and disturbs the multicellular CNS scar development in a male mouse model of TBI. Our results further demonstrate a specific deficit in the formation of the glial limitans border and establish that paracrine signaling pathways induced by NF-κB-activated astrocytes can prevent a beneficial restoration of the CNS integrity after TBI. These findings enhance our understanding on the NF-κB-mediated post-traumatic pathophysiology and provide information on future targeted therapies to improve TBI outcome.

The secondary neuroinflammatory immune response determines the overall clinical outcome after traumatic brain injury (TBI). Here, the authors show in a mouse TBI model that NF-kB activation in astrocytes is a pathological mechanism limiting beneficial CNS wound healing.

## Linked entities

- **Proteins:** NFKB1 (nuclear factor kappa B subunit 1)
- **Diseases:** traumatic brain injury (MONDO:0858950)

## Full-text entities

- **Genes:** Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, COL4A3 (collagen type IV alpha 3 chain) [NCBI Gene 1285] {aka ATS2, ATS3, ATS3A, ATS3B, BFH2}, Nfe2l2 (nuclear factor, erythroid derived 2, like 2) [NCBI Gene 18024] {aka Nrf2}, Iba1 (induction of brown adipocytes 1) [NCBI Gene 114737], Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Aim2 (absent in melanoma 2) [NCBI Gene 383619] {aka Gm1313, Ifi210}, Cd44 (CD44 antigen) [NCBI Gene 12505] {aka HERMES, Ly-24, Pgp-1}, Cspg4 (chondroitin sulfate proteoglycan 4) [NCBI Gene 121021] {aka 4732461B14Rik, AN2, Cspg4a, NG2}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, Ighg2b (immunoglobulin heavy constant gamma 2B) [NCBI Gene 16016] {aka IgG2b, Igh-3, gamma2b}, Vcan (versican) [NCBI Gene 13003] {aka 5430420N07Rik, 9430051N09, Cspg2, DPEAAE, PG-M, PG-M(V0)}, Cd3e (CD3 antigen, epsilon polypeptide) [NCBI Gene 12501] {aka CD3, CD3epsilon, T3e}, Dcn (decorin) [NCBI Gene 13179] {aka DC, DSPG2, PG40, PGII, PGS2, SLRR1B}, Lyz2 (lysozyme 2) [NCBI Gene 17105] {aka Lys, Lysm, Lyzf2, Lyzs, Lzm, Lzm-s1}, Slc1a3 (solute carrier family 1 (glial high affinity glutamate transporter), member 3) [NCBI Gene 20512] {aka B430115D02Rik, Eaat1, GLAST, GLAST-1, GLU-T, GluT-1}, Ly6g (lymphocyte antigen 6 family member G) [NCBI Gene 546644] {aka Gr-1, Gr1, Ly-6G}, LCN2 (lipocalin 2) [NCBI Gene 3934] {aka 24p3, MSFI, NGAL, p25}, PTN (pleiotrophin) [NCBI Gene 5764] {aka HARP, HB-GAM, HBBM, HBGF-8, HBGF8, HBNF}, Itgax (integrin alpha X) [NCBI Gene 16411] {aka Cd11c, Cr4, N418}, Mmp12 (matrix metallopeptidase 12) [NCBI Gene 17381] {aka MME, Mmel}, Apc (APC, WNT signaling pathway regulator) [NCBI Gene 11789] {aka CC1, Min, mAPC}, Stat1 (signal transducer and activator of transcription 1) [NCBI Gene 20846] {aka 2010005J02Rik}, Irf1 (interferon regulatory factor 1) [NCBI Gene 16362] {aka Irf-1}, MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, GFAP (glial fibrillary acidic protein) [NCBI Gene 2670] {aka ALXDRD}, Gfap (glial fibrillary acidic protein) [NCBI Gene 14580], Msr1 (macrophage scavenger receptor 1) [NCBI Gene 20288] {aka MRS-A, MSR, MSR-A, SR-A, SR-AI, SR-AII}, Eif2s2 (eukaryotic translation initiation factor 2 subunit 2 beta) [NCBI Gene 67204] {aka 2810026E11Rik, 38kDa, D2Ertd303e, EIF2, EIF2B}, Fcr (Fc receptor) [NCBI Gene 109615], SPP1 (secreted phosphoprotein 1) [NCBI Gene 6696] {aka BNSP, BSPI, ETA-1, OPN}, Ikbkb (inhibitor of kappaB kinase beta) [NCBI Gene 16150] {aka IKK-2, IKK-B, IKK-beta, IKK2, IKK[b], IKKbeta}, Hmox1 (heme oxygenase 1) [NCBI Gene 15368] {aka D8Wsu38e, HO-1, HO1, Hemox, Hmox, Hsp32}, H2 (histocompatibility-2, MHC) [NCBI Gene 111364] {aka H-2, MHC-II}, Lgals3 (lectin, galactose binding, soluble 3) [NCBI Gene 16854] {aka GBP, L-34, Mac-2, gal3}, Nlrp3 (NLR family, pyrin domain containing 3) [NCBI Gene 216799] {aka AGTAVPRL, AII/AVP, Cias1, FCAS, FCU, MWS}, TGFB2 (transforming growth factor beta 2) [NCBI Gene 7042] {aka CAEND2, G-TSF, LDS4, TGF-beta2}, HMOX1 (heme oxygenase 1) [NCBI Gene 3162] {aka HMOX1D, HO-1, HSP32, bK286B10}, Ptprc (protein tyrosine phosphatase receptor type C) [NCBI Gene 19264] {aka B220, CD45R, Cd45, L-CA, Ly-5, Lyt-4}, Hprt1 (hypoxanthine phosphoribosyltransferase 1) [NCBI Gene 15452] {aka HPGRT, Hprt}, Sts (steroid sulfatase) [NCBI Gene 20905] {aka ArsC}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, Gpnmb (glycoprotein (transmembrane) nmb) [NCBI Gene 93695] {aka DC-HIL, Dchil, ipd}, Itgam (integrin alpha M) [NCBI Gene 16409] {aka CD11b/CD18, CR3, CR3A, Cd11b, F730045J24Rik, Ly-40}, Chst11 (carbohydrate sulfotransferase 11) [NCBI Gene 58250] {aka 1110020P09Rik, C4ST, C4ST-1, C4ST1, C4s}, Cd8a (CD8 subunit alpha) [NCBI Gene 12525] {aka Ly-2, Ly-35, Ly-B, Lyt-2}, ITGAX (integrin subunit alpha X) [NCBI Gene 3687] {aka CD11C, SLEB6}, Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, Lcn2 (lipocalin 2) [NCBI Gene 16819] {aka 24p3, NRL, Sip24}, Mrc1 (mannose receptor, C type 1) [NCBI Gene 17533] {aka CD206, MR}, Cst7 (cystatin F (leukocystatin)) [NCBI Gene 13011] {aka Cmap}, Tgm2 (transglutaminase 2, C polypeptide) [NCBI Gene 21817] {aka G[a]h, TG2, TGase2, tTG, tTGas}, ITGAM (integrin subunit alpha M) [NCBI Gene 3684] {aka CD11B, CR3A, HNA-4, MAC-1, MAC1A, MO1A}, Fn1 (fibronectin 1) [NCBI Gene 14268] {aka E330027I09, Fn, Fn-1}, Jak2 (Janus kinase 2) [NCBI Gene 16452] {aka Fd17}, TGM1 (transglutaminase 1) [NCBI Gene 7051] {aka ARCI1, ICR2, KTG, LI, LI1, TGASE}, Cstb (cystatin B) [NCBI Gene 13014] {aka Stfb}, Tgm1 (transglutaminase 1, K polypeptide) [NCBI Gene 21816] {aka 2310004J08Rik, Tgase1}
- **Diseases:** hematoma (MESH:D006406), gliosis (MESH:D005911), melanoma 2 (MESH:D008545), inflammation (MESH:D007249), neurodegeneration (MESH:D019636), Traumatic (MESH:D014947), brain damage (MESH:D001925), death (MESH:D003643), brain lesion (MESH:D001927), brain injury (MESH:D001930), head injury (MESH:D006259), fracture (MESH:D050723), hypertrophy (MESH:D006984), LoF (MESH:D006315), ischemic injury (MESH:D017202), neurocognitive and neuropsychiatric morbidities (MESH:D019965), neurotoxic (MESH:D020258), Alzheimer's disease (MESH:D000544), neuroinflammation (MESH:D000090862), CNS injury (MESH:D002493), weight loss (MESH:D015431), TBI (MESH:D000070642), bleedings (MESH:D006470), GoF (MESH:D015430), CHI (MESH:D016489), stroke (MESH:D020521), neurotoxic A1 (MESH:C537088), spinal cord injury (MESH:D013119), stab wound injury (MESH:D014951), motor dysfunction (MESH:D000068079), tissue damage (MESH:D017695), damage (MESH:D020263), neurological impairments (MESH:D009422)
- **Chemicals:** sulfasalazine (MESH:D012460), NaCl (MESH:D012965), doxycycline (MESH:D004318), CAGFAP (-), Alexa Fluor  647 (MESH:C569686), glycerol (MESH:D005990), O2 (MESH:D010100), tetracycline (MESH:D013752), Dox (MESH:D004317), sodium citrate (MESH:D000077559), nitrogen (MESH:D009584), EDTA (MESH:D004492), PolyI:C (MESH:D011070), xylazine (MESH:D014991), dUTP (MESH:C027078), beta-glycerophosphate (MESH:C031463), BrdU (MESH:D001973), FITC (MESH:D016650), Alexa Fluor  488 (MESH:C000711379), Triton X-100 (MESH:D017830), glutathione (MESH:D005978), Sodium Azide (MESH:D019810), EGTA (MESH:D004533), water (MESH:D014867), NaF (MESH:D012969), isoflurane (MESH:D007530), Iron (MESH:D007501), saccharose (MESH:D013395), sodium pyrophosphate (MESH:C003319), LPS (MESH:D008070), glutamate (MESH:D018698), SDS (MESH:D012967), PBS (MESH:D007854), DTT (MESH:D004229), Tween 20 (MESH:D011136), Texas Red (MESH:C034657), Buprenorphine (MESH:D002047), poly-A (MESH:D011061), Cy5 (MESH:C085321), poly-T (MESH:D011071), DAPI (MESH:C007293)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Cavia porcellus (domestic guinea pig, species) [taxon 10141], Gallus gallus (bantam, species) [taxon 9031]
- **Mutations:** S181E, D145N, S177E
- **Cell lines:** 7.IKK2 — Mus musculus (Mouse), Finite cell line (CVCL_4W56), GoF — Bos taurus (Bovine), Spontaneously immortalized cell line (CVCL_1E25), tetO — Homo sapiens (Human), Osteosarcoma, Cancer cell line (CVCL_ZC51)

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12976058/full.md

---
Source: https://tomesphere.com/paper/PMC12976058